Shiromoto predicted that ADAR1 inhibitors could be an effective treatment for cancer patients as they interfere with two completely different pro-oncogenic functions: suppression of MDA5-MAVS-IFN signaling by the cytoplasmic ADAR1p150, and maintenance of telomere stability in telomerase-reactivated cancer cells by the nuclear ADAR1p110 [108]. Here, IFNA1 is linked to cancer.